Floryane Kim,Maxime Borgeaud,Alfredo Addeo et al.
Floryane Kim et al.
Lung cancer remains the most common cause of cancer death across the world. Non-small-cell lung cancer (NSCLC) represents the most frequent type of lung cancer and is frequently diagnosed at an advanced stage. Stage III NSCLC, which encompa...
Quantitative peritumoral magnetic resonance imaging fingerprinting improves machine learning-based prediction of overall survival in colorectal cancer [0.03%]
定量的肿瘤周磁共振成像指纹可改善基于机器学习预测结直肠癌总体存活率的能力
Azadeh Tabari,Brian D&#x;Amore,Janice Noh et al.
Azadeh Tabari et al.
Aim: To investigate magnetic resonance imaging (MRI)-based peritumoral texture features as prognostic indicators of survival in patients with colorectal liver metastasis (CRLM). ...
Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells [0.03%]
二甲双胍和电脉冲在乳腺癌MDA-MB-231细胞中的功效
Praveen Sahu,Ignacio G Camarillo,Raji Sundararajan
Praveen Sahu
Aim: Triple-negative breast cancer (TNBC) is a very aggressive subset of breast cancer, with limited treatment options, due to the lack of three commonly targeted receptors, which merits the need for novel treatments for ...
Conceptual breakthroughs of the long noncoding RNA functional system and its endogenous regulatory role in the cancerous regime [0.03%]
长链非编码RNA功能系统在癌性体系中的概念突破及其内源调控作用
Anyou Wang
Anyou Wang
Long noncoding RNAs (lncRNAs) derived from noncoding regions in the human genome were once regarded as junks with no biological significance, but recent studies have shown that these molecules are highly functional, prompting an explosion o...
Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status [0.03%]
在不同肿瘤蛋白53基因状态的非小细胞肺癌和结直肠癌细胞中对新型检查点激酶1抑制剂SRA737进行研究
Ali Jn Duabil,Christian R Cooper,Esraa Aldujaily et al.
Ali Jn Duabil et al.
Aim: In response to DNA damage the serine/threonine-specific protein kinase checkpoint kinase 1 (CHK1) is activated allowing cells to enter S phase (S) and G2 phase (G2) cell-cycle arrest. CHK1 inhibitors are expected to ...
Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma? [0.03%]
表皮生长因子受体突变的肺腺癌中的少部分进展是否是可治愈的疾病？
Sviatoslav Chekhun,Assumpció Lopez-Paradís,Aintzane Urbizu et al.
Sviatoslav Chekhun et al.
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate with a positive impact on overall survival. N...
Recent advancements in targeted protein knockdown technologies-emerging paradigms for targeted therapy [0.03%]
靶向蛋白敲除技术的近期进展-靶向治疗的新模式
Mansi Joshi,Pranay Dey,Abhijit De
Mansi Joshi
A generalized therapeutic strategy for various disease conditions, including cancer, is to deplete or inactivate harmful protein targets. Various forms of protein or gene silencing molecules, e.g., small molecule inhibitors, RNA interferenc...
Unexpected "Lazarus response" to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer [0.03%]
抗血管内皮生长因子单药治疗HER2阳性乳腺癌出现意外“枯树逢春”反应
Alexey V Emshanov,Denis V Nesterov,Tatyana N Sokolova et al.
Alexey V Emshanov et al.
Early clinical trials aimed to halt cancer progression by inhibiting the growth of new blood vessels in tumors through single-agent targeted therapy with bevacizumab. These trials largely proved unsuccessful. However, bevacizumab turned out...
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis [0.03%]
间变性淋巴瘤激酶阳性非小细胞肺癌一线治疗方案的疗效和安全性比较——网络Meta分析
Marco Filetti,Pasquale Lombardi,Rosa Falcone et al.
Marco Filetti et al.
Aim: This article is based on our previous research, which was presented as a post at the Congress Aiom 2022 Congress and published in Tumori Journal as Conference Abstract (Tumori J. 2022;108:1-194. doi: 10.1177/03008916...
Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy [0.03%]
针对神经母细胞瘤的GD2嵌合单链可变片段-人免疫球蛋白G结晶片段抗体靶向免疫治疗
Witida Laopajon,Nuchjira Takheaw,Kamonporn Kotemul et al.
Witida Laopajon et al.
Aim: The present study aims to generate chimeric mouse single-chain variable fragment (scFv) and immunoglobulin G1 (IgG1) crystallizable fragment (Fc) antibody against disialoganglioside (GD2) for the treatment of neurobl...